WO2003052068A3 - Mbcats as modifiers of the beta-catenin pathway and methods of use - Google Patents

Mbcats as modifiers of the beta-catenin pathway and methods of use Download PDF

Info

Publication number
WO2003052068A3
WO2003052068A3 PCT/US2002/039796 US0239796W WO03052068A3 WO 2003052068 A3 WO2003052068 A3 WO 2003052068A3 US 0239796 W US0239796 W US 0239796W WO 03052068 A3 WO03052068 A3 WO 03052068A3
Authority
WO
WIPO (PCT)
Prior art keywords
beta
methods
mbcats
modifiers
catenin pathway
Prior art date
Application number
PCT/US2002/039796
Other languages
French (fr)
Other versions
WO2003052068A2 (en
Inventor
Michael A Costa
Steven Brian Gendreau
Emery G Dora Iii
Monique Nicoll
Original Assignee
Exelixis Inc
Michael A Costa
Steven Brian Gendreau
Emery G Dora Iii
Monique Nicoll
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Michael A Costa, Steven Brian Gendreau, Emery G Dora Iii, Monique Nicoll filed Critical Exelixis Inc
Priority to AU2002361654A priority Critical patent/AU2002361654A1/en
Publication of WO2003052068A2 publication Critical patent/WO2003052068A2/en
Publication of WO2003052068A3 publication Critical patent/WO2003052068A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Human MBCAT genes are identified as modulators of the beta-catenin pathway, and thus are therapeutic targets for disorders associated with defective beta-catenin function. Methods for identifying modulators of beta-catenin, comprising screening for agents that modulate the activity of MBCAT are provided.
PCT/US2002/039796 2001-12-13 2002-12-12 Mbcats as modifiers of the beta-catenin pathway and methods of use WO2003052068A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002361654A AU2002361654A1 (en) 2001-12-13 2002-12-12 Mbcats as modifiers of the beta-catenin pathway and methods of use

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US34032201P 2001-12-13 2001-12-13
US34031401P 2001-12-13 2001-12-13
US34021301P 2001-12-13 2001-12-13
US60/340,322 2001-12-13
US60/340,213 2001-12-13
US60/340,314 2001-12-13
US35750202P 2002-02-15 2002-02-15
US60/357,502 2002-02-15

Publications (2)

Publication Number Publication Date
WO2003052068A2 WO2003052068A2 (en) 2003-06-26
WO2003052068A3 true WO2003052068A3 (en) 2003-10-09

Family

ID=27502619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/039796 WO2003052068A2 (en) 2001-12-13 2002-12-12 Mbcats as modifiers of the beta-catenin pathway and methods of use

Country Status (2)

Country Link
AU (1) AU2002361654A1 (en)
WO (1) WO2003052068A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2535897A1 (en) * 2003-08-14 2005-02-24 Exelixis, Inc. Sulfs as modifiers of the beta catenin pathway and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998600A (en) * 1997-03-20 1999-12-07 Utrecht University β-catenin, TCF-4, and APC interact to prevent cancer
US6303576B1 (en) * 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998600A (en) * 1997-03-20 1999-12-07 Utrecht University β-catenin, TCF-4, and APC interact to prevent cancer
US6303576B1 (en) * 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PEER BORK: "Powers and pitfalls in sequence analysis: the 70% hurdle", GENOME RESEARCH, vol. 10, 2000, pages 398 - 400, XP002961676 *

Also Published As

Publication number Publication date
AU2002361654A1 (en) 2003-06-30
WO2003052068A2 (en) 2003-06-26
AU2002361654A8 (en) 2003-06-30

Similar Documents

Publication Publication Date Title
WO2002099047A3 (en) PROMLs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2002099074A8 (en) Slc7s as modifiers of the p53 pathway and methods of use
WO2003073823A3 (en) PDPK1s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2003014301A3 (en) Hprp4s as modifiers of the p53 pathway and methods of use
WO2003051905A3 (en) Taojiks as modifiers of the beta-catenin pathway and methods of use
WO2002099043A3 (en) P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2004013309A3 (en) PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE
WO2003035831A3 (en) Lrrcaps as modifiers of the p53 pathway and methods of use
WO2003052068A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004014301A3 (en) PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE
WO2004065542A3 (en) MAT2As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2003074725A3 (en) MBCATs AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE
WO2004061123A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004048538A3 (en) Csnks as modifiers of the rac pathway and methods of use
WO2004083389A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004048541A3 (en) Cct6s as modifiers of the rb pathway and methods of use
WO2003074671A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004047761A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2003074673A3 (en) Lgals as modifiers of the chk pathway and methods of use
WO2003074677A3 (en) MCHKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE
WO2003033656A3 (en) MSREBPs AS MODIFIERS OF THE SREBP PATHWAY AND METHODS OF USE
WO2004083447A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2003066811A3 (en) Msrebps as modifiers of the srebp pathway and methods of use
WO2003052070A3 (en) Vps41s as modifiers of cell death and methods of use
WO2003052066A3 (en) Klcs as modifiers of the p53 pathway and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP